Will Palbociclib be included in medical insurance in 2024?

Palbociclib (Palbociclib) The original drug has been launched in China and is sold under the name of Palbociclib Capsules (Aiboxin). As ofthe end of December 2023, palbociclib capsules have passed the relevant regulations of the National Medical Insurance Bureau and entered the scope of Class B medical insurance reimbursement, but only patients who meet the indications can be reimbursed. The reimbursement ratio is different in different regions, and the price after reimbursement may be different, but the quoted price will be much cheaper than the original price.

Palbociclib is the first oral CDK4/6 inhibitor to show significantly improved median progression-free survival (PFS) in advanced estrogen receptor (ER)-positive and human epidermal growth factor receptor 2 (HER2)-negative breast cancer. This prolongation in PFS was seen both with letrozole as first-line therapy (24.8 months versus 14.5 months [PALOMA2 trial]) and with fulvestrant as endocrine conditioning in patients (9.2 months versus 3.8 months [PALOMA3 trial]). The major toxicity is neutropenia due to cell cycle arrest, which can be easily managed by dose interruption or dose reduction, resulting in a good safety profile and delayed deterioration in overall quality of life (QoL).

The domestically marketed palbociclibOriginal drug, common specificationsThe price of 100mg*21 pills per box may be more than 6,000 yuan, while the price of the original drug sold overseas is even more expensive, and the price of 125mg*21 pills per box may be around 10,000 yuan (the price may fluctuate due to exchange rates). Palbociclib generics are also sold overseas. The ingredients are basically the same as those sold domestically and abroad, but the price is cheap. For example, the price of a box of 125mg*21 tablets produced by a Bangladesh pharmaceutical factory may be several hundred yuan (prices may fluctuate due to exchange rates).